INTRODUCTION
Diabetes mellitus is a progressive and chronic disease which is a major healthcare problem worldwide. According to the World Health Organization, 347 million people worldwide have diabetes (both types 1 and 2) [1] , and the number is estimated to rise to 592 million by 2035, as forecasted by the International Diabetes Federation [2] . Type 2 diabetes mellitus (T2DM) results from a combination of insulin resistance and insulin deficiency. It is the most prevalent type of diabetes, accounting for 95% or more of all diabetes cases globally [3] .
Diabetes can lead to many serious microvascular degenerative complications (e.g., retinopathy, nephropathy, and neuropathy) resulting into an increased risk of morbidity and mortality and with this significant health care system costs [4] . Hence, while, ideally, the treatment of diabetes demands a holistic approach that can address various complications associated with diabetes, the primary target of achieving an adequate blood glucose level as measured by hemoglobin A1c (HbA1c) level seems still essential. In fact, in previous studies in patients with T2DM, an association between the degree of hyperglycemia and a high risk of microvascular complications has been shown [5, 6] . Several prospective observational studies have outlined the role of intensive glucose control in reducing the risk of microvascular complications in diabetes [7, 8] . Some of the important drugs that are widely used in the treatment of T2DM are metformin, sulfonylureas, and thiazolidinediones class of molecules [4] .
Dipeptidyl peptidase-4 (DPP-4) inhibitors were introduced in the treatment of T2DM in 2006 [9] . DPP-4 is an endogenous aminopeptidase enzyme which degrades incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibitors impart their action by increasing the endogenous concentrations of GLP-1 and GIP that are released in response to food intake [10, 11] . The increased concentration of GLP-1 and GIP lead to insulin secretion by pancreatic b-cells, decreased glucagon secretion, and reduction in liver glucose production. Due to their efficacy, good tolerability, low risk of hypoglycemia, and body-weight neutrality, DPP-4 inhibitors have gained importance in the treatment of T2DM [12] . Vildagliptin (Galvus Ò ; Novartis Pharma AG) is an oral antidiabetic agent from the DPP-4 inhibitor class of drugs. It is indicated in Europe in the treatment of T2DM on its own (monotherapy) in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance; together with metformin, a thiazolidinedione or a sulfonylurea (dual therapy); or together with a sulfonylurea and metformin (triple therapy). Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control [3] .
Several studies have indicated importance of sulfonylureas or insulin to reduce the risk of microvascular complications [13] . However, there is no adequate comparative data available on the role of a relatively new molecule, i.e., a DPP-4 inhibitor vildagliptin, in treating the microvascular complications associated with T2DM. In this study, we used real-world evidence to evaluate the role of vildagliptin in treating microvascular complications associated with T2DM and compared it with sulfonylurea. The main objectives were to evaluate the incidence of microvascular complications of diabetes between the two treatment groups, i.e., vildagliptin vs. sulfonylurea, as well as, to investigate time needed for the development of these complications between patients in the above-mentioned populations.
METHODS

Study Design
The main objective of the study was to compare the incidence of the defined and confirmed microvascular event outcomes following exposure to one of two therapies: vildagliptin and sulfonylurea. To achieve this objective, a retrospective cohort study design was used in which exposure, outcome, and possible confounding variables were measureable. Since the source of data was longitudinal electronic medical record (EMR), the cohorts were defined by diagnoses and exposures recorded historically, with outcomes tracked over the course of the study period. As such, there was no need for patient informed consent and ethical committee approval according to the German and European law. To avoid confounding between comparison groups of vildagliptin vs. sulfonylurea, matched samples were created using propensity score matching (see ''Statistical Analysis'' subsection for details).
Outcomes
The primary endpoint was defined as the first recorded occurrence of diabetic nephropathy (ICD-10 codes: E11.2, E14.2), diabetic retinopathy (ICD-10 codes: E11.3, E14.3), diabetic neuropathy (ICD-10 codes: E11.4, 14.4), and diabetic foot syndrome (DFS; through natural language processing, as there is no ICD-10 code for this pathology).
In addition, a combined endpoint of first 
Statistical Analysis
Descriptive statistics were calculated for all study variables and consist of number and percentage for categorical variables, as well as mean, median, minimum, maximum, and standard deviation for continuous variables with 95% confidence interval (CI).
The primary outcomes, as defined above, were assessed by unadjusted and adjusted odds ratios (ORs; with 95% CI), expressing the difference in risk of microvascular events (individual and combined) for patients prescribed vildagliptin or sulfonylurea. CIs were estimated using the Miettinen-Nurminen method.
Secondary outcomes (time-to-microvascular event) were analyzed using Kaplan-Meier survival curves and the log-rank test. Incident rate ratios (IRR) were also calculated for different microvascular complications comparing two treatment groups (vildagliptin vs. sulfonylurea).
To account for potential confounding factors between two study groups (vildagliptin vs. sulfonylurea), matched samples were created using propensity score matching, i.e., the vildagliptin and sulfonylurea groups were selected to have similar profiles of propensity scores. The propensity scores were derived from the probability of treatment assignment conditional on the following confounding factors (covariates): age, sex, line of therapy, HbA1c score, duration of disease (\5 years vs.
C5 years), duration of treatment, previous hypoglycemic events, co-prescribed medications, and number of co-morbidities.
These confounding factors could act as potential sources of bias in evaluating main objectives of the study, and hence, patients with similar demographic and clinical characteristics in two study groups (matched samples) were pooled. Propensity score-based matching criteria with respect to various confounding factors were used to derive matched samples between two study groups.
Propensity scores were generated using a logistic regression model and matched using a genetic algorithm for closest matching based on propensity scores and covariate balance. The distribution of propensity scores and covariates was examined by group to allow for the degree of matching to be quantified (see Fig. 1 ). 
RESULTS
Participants and Cohort Characteristics
To investigate incidences of microvascular Tables 2 and 3 .
Incidences of Microvascular
Complications
Primary endpoint of the present investigation was to measure the first occurrence of microvascular complications in diabetic patients which were assigned to vildagliptin or sulfonylurea treatments. Particularly incidences for retinopathy, nephropathy, neuropathy, DFS, or composite (occurrence of any of above complications) outcomes were measured Table S3 ).
Incidences of each microvascular complications, i.e., retinopathy, nephropathy, neuropathy, DFS, or composite, appeared higher in the sulfonylurea study arm when compared with the vildagliptin arm (Table 4 ).
To enable direct comparison between study arms, ORs based on incidences for each Table 5 and Fig. 2) . Differences were non-significant for nephropathy (OR 
DISCUSSION
A retrospective cohort observational study was carried out to investigate any advantage of the relatively new DPP-4 inhibitors class of a drug Our investigations in the present study indicate that treatment with vildagliptin is associated with lower overall incidences of microvascular events, particularly significant were retinopathy and neuropathy, when Relevant patients' data for the present study were extracted from the IMS Lifelink EMR DA database for the German population. The study design (retrospective cohort study) prevents any claims to have established causal effects based on the observed associations. A further limitation of database studies using EMR data is the suboptimal recording of information by physicians. However, in this study, the assumption could be made that this suboptimal recording affects both exposure groups (vildagliptin vs. sulfonylurea) in the same way, and thus, under-reporting may not be an issue for this real-world evidence comparison. Nevertheless, any conclusion regarding the absolute incidence of each microvascular complication shall be handled with caution. In addition, the under-reporting can potentially reduce the effect size, the amount of which cannot be estimated from the study data. It is likely that patients' exposure to vildagliptin or sulfonylurea was determined by their profile which, in its turn, affects the development of microvascular complications. We have tried to reduce or [14] .
DPP-4 inhibitors have shown potential for the management of T2DM, as corroborated by conducted clinical trials that have indicated safety and efficacy of vildagliptin and other DPP-4 inhibitors in the treatment of T2DM [15] [16] [17] [18] [19] [20] . Vildagliptin is well-tolerated and produces clinically meaningful reduction in blood glucose level without promoting weight gain or inducing hypoglycemia [21] . Recent studies have shown advantages of vildagliptin in T2DM treatment in elderly [22] and overweight/obese patients [23] . The benefit of DPP-4 inhibitors in addressing cardiovascular risks associated with T2DM when compared with, e.g., the metformin therapy was also investigated in several studies [12, 24, 25] . studies based on real-world data will be one step forward toward achieving the tailor-made, patient-centered approach for the treatment of a chronic disease, such as diabetes.
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